Cargando…

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C

We aimed to examine the relationship between renal dysfunction and anaemia that may develop during combination therapy involving pegylated interferon, ribavirin and telaprevir (PEG-IFN/RBV/TVR) for the treatment of chronic hepatitis C. Sixty-eight patients with genotype 1b high viral loads were trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karino, Y, Ozeki, I, Hige, S, Kimura, M, Arakawa, T, Nakajima, T, Kuwata, Y, Sato, T, Ohmura, T, Toyota, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282353/ https://www.ncbi.nlm.nih.gov/pubmed/24001168 http://dx.doi.org/10.1111/jvh.12162

Ejemplares similares

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
por: Suii, Hirokazu, et al.
Publicado: (2017)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Telaprevir
Publicado: (2012)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b
por: Toyota, J, et al.
Publicado: (2013)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study
por: Janczewska, Ewa, et al.
Publicado: (2015)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection
por: Christensen, Stefan, et al.
Publicado: (2014)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi
por: Akar, Tarık, et al.
Publicado: (2015)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
por: Haseltine, Eric L., et al.
Publicado: (2014)

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
por: Brogan, Anita J., et al.
Publicado: (2014)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
por: Lee, Tae-Hee, et al.
Publicado: (2014)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
por: Mousa, Omar Y. S., et al.
Publicado: (2014)

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
por: Nishikawa, Hiroki, et al.
Publicado: (2012)

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
por: Asselah, Tarik, et al.
Publicado: (2010)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
por: Martins, Elson Vidal, et al.
Publicado: (2009)

Expectoration of Large Bronchial Casts Secondary to the Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin
por: de Araújo, Evaldo Stanislau Affonso, et al.
Publicado: (2010)

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jn836vbv43icalr0i9gr1cm8if